SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves steep selloff is fueling debate over its debt load, high financing costs and ability to fund AI-infrastructure expansion; bearish traders see refinancing and dilution risks, while bullish traders point to contracted demand and continued AI growth. Goldmans Buy upgrade and ARKs purchases have not eased the communitys concern about the financing outlook.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs steep decline to fresh lows is being linked by traders to Trumps falling approval and approaching midterms, with many expressing concern that weakening political support is hurting the stocks sentiment-driven appeal. Some see the selloff as a buying opportunity, but bearish reactions dominate.

Cipher Digital, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Digital Inc.

Ciphers sharp selloff is being tied mainly to its convertible-note financing and the resulting dilution and debt concerns, alongside a broader retreat in AI data-center and neocloud stocks amid scrutiny of financing costs. Traders are frustrated with management and fear further downside, while some argue the financing overhang is easing and continue to cite long-term AI-hosting demand as a reason to buy the dip.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflixs upcoming Q3 earnings report is the main focus, with traders debating whether slowing growth and engagement concerns will weigh on results and guidance. Views are split: some expect further downside, while others see pessimism and recent cost and content-leadership changes as reasons for optimism.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is drawing attention after a steep selloff in memory stocks, amid weakness in South Koreas market and concerns about Chinese competitor CXMT, AI spending and memory-cycle normalization. Traders are divided between viewing the decline and rebound as a buying opportunity given the companys fundamentals and valuation, and expecting more downside from foreign selling and continued sector pressure.

United Airlines Holdings, Inc. is a holding company, which engages in the provision of transportation services. It operates through the following geographical segments: Domestic, Atlantic, Pacific, and Latin America. The company was founded on December 30, 1968 and is headquartered in Chicago, IL.

United Airlines Holdings Inc

Attention centers on Uniteds upcoming quarterly results after a sharp recent selloff, with traders debating whether demand and guidance can offset elevated fuel costs. A separate wave of criticism over CEO Scott Kirbys inheritance-tax remarks has prompted boycott and sell calls, though any business or market impact remains speculative.

Kratos Defense & Security Solutions, Inc. engages in the provision of mission critical products, services and solutions for United States national security priorities. It operates through the Kratos Government Solutions (KGS) and Unmanned Systems (US) segments. The KGS segment consists of an aggregation of KGS operating segments, including microwave electronic products, space, satellite and cyber, training solutions. The US segment refers to the unmanned aerial, unmanned ground, unmanned seaborne and related command, control and communications system businesses. The company was founded on December 19, 1994, and is headquartered in Round Rock, TX.

Kratos Defense & Security Solutions Inc

KTOS is drawing attention for its prolonged selloff and repeated lows, despite defense-contract news and bullish analyst coverage. Traders debate whether the decline reflects sector pressure and an expensive valuation, alongside dilution and insider-sale concerns, or creates an opportunity based on Kratoss longer-term drone and defense growth prospects.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A steep semiconductor selloff, amid concerns about AI spending, financing risks, and whether chip demand can justify the investment boom, has driven attention to SOXL; the funds sharp rebound has sparked a divide between dip buyers expecting a recovery and traders who see a temporary bounce before further declines. The leveraged ETF amplifies the sectors swings, and traders are watching upcoming earnings and spending commentary for evidence that AI demand remains robust.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

Ahead of SpaceXs Q3 report, traders are focused on whether AI-compute investment can drive revenue growth and profitability; optimism about AI and Starlink expansion is countered by concerns about heavy spending and upcoming share unlocks. Musks pledge to give a SpaceX share to every U.S. child is also drawing attention, though implementation details remain unclear.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

A rebound in semiconductor stocks has lifted SOXX after a prolonged selloff, but traders remain divided on whether it signals stabilization or a temporary bounce. The debate centers on persistent AI-demand optimism versus concerns about spending returns, financing stress and the sectors steep decline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss — Executive ‘Disappointed,’ Reiterates Breast Cancer Focus 

Equity

A combination of the company’s breast cancer drug Etcamah did not delay worsening of the disease enough to meet the SERENA-4 late-stage trial’s main goal, AstraZeneca said. 


NVO Stock Jumps 3% As EU Approves Oral Wegovy Pill — Retail Notes LLY Is ‘Clearly Behind’ Its Danish Counterpart

Oral Wegovy is now cleared in all EU member states.


NVO Stock Gains As UK Clears First Daily GLP-1 Weight-Loss Pill, Offsetting Security Breach News

Novo Nordisk revealed that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved the Wegovy pill, following in the footsteps of the U.S. FDA. 


AZN Stock Rise As Wall Street Dismisses FDA Committee’s Rejection Of Breast Cancer Drug 

FDA’s Oncologic Drugs Advisory Committee (ODAC) did not reach a majority vote on the benefit-risk profile of AstraZeneca’s camizestrant in combination with other drugs. 

Novo Nordisk Launches Higher Dose Of Wegovy Injection Across US — Retail Thinks Stock Is ‘Terribly Undervalued’

The Wegovy HD injection 7.2 mg will be available through over 70,000 U.S. pharmacies including Novo’s own NovoCare Pharmacy and select telehealth providers, the company said.


Novo Nordisk Receives FDA Approval For Higher Dose Of Its Weight-Loss Drug Wegovy

The company stated that Wegovy HD received the FDA’s accelerated approval based on results from the STEP UP trial.

Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock

BMO Capital maintained its ‘Market Perform’ rating for Novo Nordisk, with a price target of $45, implying an upside of more than 13% from NVO stock’s closing price on Monday.

HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy

Hims & Hers also stated that it will no longer advertise compounded GLP-1 offerings on its platform or in its marketing.

Novo Nordisk To Cut Ozempic, Wegovy Prices By Up To 50%

Ozempic and Wegovy will start at a list price of $675 a month, effective Jan. 1, 2027, according to the company.

NVO Stock Continues To Decline Pre-Market After Monday’s Crash Amid CagriSema Setback – But Tuesday Brings Some Hope From China

Developed in partnership with United Laboratories International Holdings, Novo Nordisk said that UBT251 delivered up to 19.7% mean weight loss after 24 weeks in a phase 2 trial in China.

Putnam ETF Trust - Putnam Focused Large Cap Value ETF

Neutral Sentiment

<ul class="summary-bullets"><li>AstraZeneca, however, said progression-free survival improved numerically.&nbsp;</li><li>Etcamah is a once-daily pill that breaks down the estrogen receptor many breast cancers use to grow and is already approved for a narrower group of breast cancer patients.&nbsp;</li><li>The setback lands on a pipeline already under scrutiny.</li></ul><p>Shares of AstraZeneca traded 3% lower in after-hours trading on Friday after the drugmaker said a large late-stage breast cancer study of Etcamah missed its main goal, denting hopes of a broader first-line use for one of its most closely watched oncology assets.</p><h2 class="st-heading-2">What The Trial Showed</h2><p>The trial SERENA-4 tested Etcamah plus palbociclib against a standard hormone-blocking pill plus palbociclib in 1,371 people starting treatment for advanced hormone-sensitive breast cancer that is not HER2-driven. The Etcamah combination did not delay disease progression enough to meet the trial’s main goal, though AstraZeneca said there was a numerical improvement. Side effects were in line with what is already known for both drugs. The company said it will present full results later.</p><p>Etcamah is a once-daily pill that breaks down the estrogen receptor many breast cancers use to grow. It is already approved in the United States, Europe, Japan and other markets for a narrower group: patients whose tumors pick up a common resistance mutation called ESR1 while they are on first-line hormone therapy. That use is based on an earlier SERENA-6 trial.</p><p>Friday’s miss undercuts the case for giving the drug to all newly diagnosed advanced patients from the start, before that mutation appears.</p><h2 class="st-heading-2">Another Hit After A Rough Year</h2><p>The setback lands on a pipeline already under scrutiny. In July, AstraZeneca’s heart drug Wainua failed a major heart-disease trial, triggering a steep one-day drop. Rare-disease medicine Ultomiris also missed a rare-disease study. In August, AstraZeneca halted a late-stage lung cancer trial of volrustomig after an independent committee said it was unlikely to beat standard immunotherapy.</p><p>Those blows have helped drag the stock down about 20% over six months even as core cancer sales remain a pillar of the business.</p><p>Oncology accounts for a large share of AstraZeneca’s growth. Without a broad first-line label in advanced disease, Etcamah’s near-term commercial reach is smaller. Oncology research chief Susan Galbraith called SERENA-4 disappointing but said the company remains confident in the drug’s longer-term potential in early breast cancer.</p><p>Two separate large trials, CAMBRIA-1 and CAMBRIA-2, are testing Etcamah after surgery in about 10,000 patients to see if it can cut the risk of recurrence.</p><h2 class="st-heading-2">How Did AZN Retail Traders React?</h2><p>On Stocktwits, retail sentiment around AZN stock stayed in ‘bearish’ territory over the past 24 hours, while message volume was ‘high.’</p><p><a href="https://stocktwits.com/symbol/AZN">AZN stock</a> has fallen 9% year-to-date.&nbsp;</p><p>Read More: <a href="https://stocktwits.com/news-articles/markets/equity/exel-stock-slides-after-fda-adds-three-months-to-cancer-drug-review-william-blair-sees-more-swings-in-near-term/cZtXM0eRBbg">EXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

The international biopharmaceutical company Astrazeneca office building in Shanghai, China on June 27, 2025. (Photo credit should read CFOTO/Future Publishing via Getty Images)

A combination of the company’s breast cancer drug Etcamah did not delay worsening of the disease enough to meet the SERENA-4 late-stage trial’s main goal, AstraZeneca said. 

AZN Stock Slips After-Hours Following Latest Late-Stage Oncology Trial Miss — Executive ‘Disappointed,’ Reiterates Breast Cancer Focus

American Century ETF Trust - Avantis International Equity ETF

AstraZeneca PLC

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Stocktwits

Meta Platforms Inc

Which earnings release are you most looking forward to this week: 

Feed

News

Sentiment

Fundamentals

Info

PVAL Putnam ETF Trust - Putnam Focused Large Cap Value ETF

Fundamentals

Latest PVAL News